US5627159A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Enhancement of lipid cationic transfections in the presence of serum
Assignee: Life Technologies Corp
•
Filing: 1994-10-27
•
Granted: 1997-05-06
•
Expires: 2014-10-27
Abstract
Abstract A method is provided for enhancing transfection efficiency of eukaryotic cells comprising contacting said cells with a lipid aggregate comprising nucleic acid and a polycationic lipid composition in the presence of a polycationic compound and serum. The polycationic compound is preferably Polybrene™, and the lipid aggregate preferably comprises liposomes of nucleic acid and LipofectAMINE™.
Inventors
- 👤 PoJen Shih
- 👤 Pamela Hawley-Nelson
- 👤 Joel A. Jessee
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 16:02
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K9/1271; A61K9/1272; C; C12; C12N; C12N15/00; C12N15/09; C12N15/87
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
55 words
In a method of transfecting an animal cell in the presence of serum, comprising contacting said cell with a lipid aggregate comprising nucleic acid and a cationic lipid, wherein the improvement comprises: contacting said cell with said lipid aggregate in the presence of a polycationic compound, thereby transfecting said animal cell with said nucleic acid.
Claim 2
Dependent Claim
55 words
In a method of transfecting an animal cell in the presence of serum, comprising contacting said cell with a lipid aggregate comprising nucleic acid and a cationic lipid, wherein the improvement comprises: contacting said cell with said lipid aggregate in the presence of a polycationic compound, thereby transfecting said animal cell with said nucleic acid.
Claim 3
Dependent Claim
95 words
In a method of transfecting an animal cell in the presence of serum, comprising contacting said cell with a lipid aggregate comprising nucleic acid and a cationic lipid, wherein the improvement comprises: either (a) first contacting said cell with a polycationic compound to form a complex of said cell with said polycationic compound followed by contacting said cell complex with said lipid aggregate; or (b) first contacting said lipid aggregate with said polycation compound to form a mixture followed by contacting said cell with said mixture, thereby transfecting said animal cell with said nucleic acid.
Claim 4
Dependent Claim
95 words
In a method of transfecting an animal cell in the presence of serum, comprising contacting said cell with a lipid aggregate comprising nucleic acid and a cationic lipid, wherein the improvement comprises: either (a) first contacting said cell with a polycationic compound to form a complex of said cell with said polycationic compound followed by contacting said cell complex with said lipid aggregate; or (b) first contacting said lipid aggregate with said polycation compound to form a mixture followed by contacting said cell with said mixture, thereby transfecting said animal cell with said nucleic acid.
Claim 5
Dependent Claim
11 words
A method of claim 2 wherein said polycationic compound is POLYBRENE™.
Claim 6
Dependent Claim
16 words
A method of claim 2 wherein said lipid aggregate comprises a compound toxic to said cells.
Claim 7
Dependent Claim
11 words
A method of claim 2 wherein said cells are mammalian cells.
Claim 8
Dependent Claim
12 words
A method of claim 2 wherein said serum is fetal bovine serum.
Claim 9
Dependent Claim
11 words
A method of claim 2 wherein said serum is human serum.
Claim 10
Dependent Claim
11 words
A method of claim 2 wherein said lipid aggregate comprises LipofectAMINE™.
Claim 11
Dependent Claim
11 words
A method of claim 2 wherein said lipid aggregate comprises Lipofectin™.
Claim 12
Dependent Claim
11 words
A method of claim 2 wherein said lipid aggregate comprises LipofectACE™.
Claim 13
Dependent Claim
11 words
A method of claim 2 wherein said nucleic acid is DNA.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-05-05 | 2000-11-04 | 2001-05-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-05-05 | 2004-11-04 | 2005-05-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-05-05 | 2008-11-04 | 2009-05-06 | $7700.00 | Window Closed / Lapsed |